Clinical Trials Directory

Trials / Completed

CompletedNCT00114439

Lithium Cannabis Withdrawal Study

An Open Label Trial of Lithium for the Management of Cannabis Withdrawal

Status
Completed
Phase
Phase 2
Study type
Interventional
Enrollment
25 (estimated)
Sponsor
Sydney South West Area Health Service · Other Government
Sex
All
Age
18 Years – 55 Years
Healthy volunteers
Accepted

Summary

This trial will examine the efficacy of lithium in providing symptomatic relief from the withdrawal discomfort experienced by some dependent users of cannabis on cessation of regular use. Significant withdrawal may be a barrier to achieving abstinence in some clients and can be associated with marked disturbances in mood, sleep, hostility and aggression. Relief from such symptoms may be important in helping some clients achieve a period of abstinence and facilitate subsequent entry into a relapse prevention program.

Detailed description

There are currently no accepted pharmacotherapies for the management of cannabis withdrawal. A recent study by Cui et al (2001) investigated the effects and mechanism of lithium on cannabinoid withdrawal in rats. The researchers found that lithium administration prevented the development of withdrawal symptoms, and suggested that increased oxytocin secretion resulting from lithium dosing prevented the withdrawal syndrome from occurring. Although caution should be exercised in generalising the results of an animal study, preliminary results of a small pilot study in humans are consistent with the potential utility of lithium in the management of human cannabis withdrawal (Zhang, personal communication). Furthermore, human use of lithium is well established and the addition of a readily available drug such as lithium carbonate would be a useful clinical tool should it prove efficacious in a series of clinical trials.

Conditions

Interventions

TypeNameDescription
DRUGLithium carbonate

Timeline

Start date
2005-09-01
Completion
2006-09-01
First posted
2005-06-15
Last updated
2007-09-27

Locations

1 site across 1 country: Australia

Source: ClinicalTrials.gov record NCT00114439. Inclusion in this directory is not an endorsement.